Ovid Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value
Ovid Therapeutics Inc. (OVID) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value of $6.34 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue · last filed 2026-08-13
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $6.34M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $3.55K.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $1.00K.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value $258.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value as first filed |
|---|---|---|
| 2026-06-30 | $6.34M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $3.55K 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $1.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $258.00 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-18 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $12.79K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $2.37M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $2.46M 10-K · filed 2026-03-18 | $2.46M 10-K · filed 2024-03-08 |
| 2023-09-30 | $5.27M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $2.41M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $694.30K 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $61.21K 10-K · filed 2025-03-11 | |
| 2022-09-30 | $56.19K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $297.95K 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $1.52M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $1.53M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $1.54M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $2.45M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $2.52M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $445.60K 10-K · filed 2023-03-13 | |
| 2020-09-30 | $1.77M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $2.93M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $429.01K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $356.44K 10-K · filed 2022-03-15 | |
| 2019-09-30 | $252.71K 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $115.69K 10-Q · filed 2019-08-07 | |
| 2018-12-31 | $153.49K 10-K · filed 2021-03-15 | |
| 2018-09-30 | $380.23K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $1.10M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $713.58K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $3.87M 10-K · filed 2020-03-11 | |
| 2016-12-31 | $253.97K 10-K · filed 2019-03-07 | |
| 2015-12-31 | $567.00K 10-K · filed 2018-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |